Navigation Links
Neuradiab in Medical News

Bradmer provides Phase III Neuradiab trial update and guidance

TSX: BMR TORONTO, Oct. 15 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that it held a pre-Phase III meeting with the U.S. Food and Drug ...

Bradmer to repurchase up to 8.3 million of its common shares pursuant to a substantial issuer bid

...equally. We continue to evaluate opportunities to maximize the value of the neuradiab asset, however a substantial portion of the existing cash on hand will be u...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer announces 2009 first quarter operational and financial results

...luate strategic options. "Despite our pride in the progress made bringing neuradiab from a single-site Phase II program to a multicenter Phase III registration...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer announces 2008 fourth quarter and fiscal year operational and financial results

...tinuing to evaluate strategic options. "We have successfully transitioned neuradiab from a Phase II compound with compelling results at a single site to a cGMP...imary GBM patients in a Phase III multi-center clinical trial of Neuradiab. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer implements cash conservation plan

...tends to maintain the ability to pursue business development strategies for neuradiab and is continuing to explore opportunities that would permit further develo...lment in a Phase III multi-center clinical trial of the licensed treatment. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administ...

Bradmer provides clinical trial update and announces evaluation of strategic alternatives

...l patient survival from 53 to 64 weeks. About neuradiab neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...

Bradmer to participate in panel presentation at RBC Capital Markets Healthcare Conference

... form of brain cancer, glioblastoma multiforme. Bradmer has initiated enrollment in a Phase III multi-center clinical trial of the licensed treatment. neuradiab has been granted Orphan Drug Status by both the U.S. Food and Drug Administration and the European Medicines Agency. Bradmer Pharmaceuticals ...

Bradmer to present poster on progression free survival and overall survival data from Neuradiab(TM) Phase II trials at Society for Neuro-Oncology Meeting

...ponse of newly diagnosed GBM patients treated with neuradiab as an adjunct to the current standard of care, con...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy, consistin...NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...

Bradmer announces 2008 third quarter operational and financial results

...ART Trial and successfully dosed patients with neuradiab at multiple sites; - Announced new data from the...llow a two week extension of the shelf life of neuradiab beyond the current six-day specification; and ...y to provide a definitive answer on the benefit of neuradiab in the newly diagnosed GBM population." The Phas...

Bradmer to present at Rodman & Renshaw Healthcare Conference

...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy, consistin...dy identifier NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...
Neuradiab in Medical Technology

Molecular Target of Bradmer's Neuradiab Further Validated by Independent Findings

TSX: BMR TORONTO, July 10, 2007 /PRNewswire-FirstCall/ - Bradmer Pharmaceuticals Inc., a biopharmaceutical company dedicated to the development and commercialization of cancer therapies, today announced that new research published by an independent team in Basel, Switzerland validates tenascin as ...

Bradmer reports progression free survival data from previous Phase II glioblastoma multiforme trials

...ical trial, termed the GLASS-ART Trial, evaluating neuradiab as an adjunct therapy to the current standard of c...e control arm. "These PFS data from the Phase II neuradiab trials exceed the results achieved in any other cl...nt of median overall survival, the opportunity for neuradiab to demonstrate a patient benefit via the parameter...
Neuradiab in Biological Technology

Bradmer sponsors physician panel to raise awareness of brain cancer treatments

...rvival benefit derived from, and safety of, adding neuradiab to the current standard of care therapy for patien...dy identifier NCT00615186. About Neuradiab(TM) neuradiab is a monoclonal antibody, conjugated to radioactiv...ost common and most advanced form of brain cancer. neuradiab delivers tumor-killing radiation specifically to r...
Other Tags
(Date:8/29/2014)... 30, 2014 Top10inaction, a professional product ... providers in the online service industry for the month ... leaders Webex, GotoMeeting and Infinite. , With over thousands ... to determine which provider is ideally a good fit ... search for compelling consumer goods and services agencies to ...
(Date:8/29/2014)... Pittsburgh, PA (PRWEB) August 29, 2014 ... inventor from Harrisburg, Pa., had to have breast reconstruction. ... to be sub-par, so she decided that there needed ... a better look for a woman or man who ... visible, as well as promotes confidence and peace of ...
(Date:8/29/2014)... The West African Ebola outbreak took a more deadly turn ... new cases this week -- the biggest jump in infections ... Liberia, the U.N. health agency said, but cases in Guinea ... reported. "There are serious problems with case management ... "The situation is worsening in Liberia and Sierra Leone." ...
(Date:8/29/2014)... ReputationChief.Com, a well-established online reputation management firm, has ... service has been launched to help individuals and organizations ... them. , In order to make sure that the ... to its clients, ReputationChief.Com has designed the service after ... , As per the indications from the company management, ...
(Date:8/29/2014)... Los Angeles, CA (PRWEB) August 29, 2014 ... Sands DDS, is now offering mini implants to area ... replaced permanently without worries of long-term teeth shifting and ... dependability associated with full-size dental implants , their ... well as faster placement and easier recovery. Once placed, ...
Breaking Medicine News(10 mins):Health News:Top10InAction Reveals Best Web Conference Providers 2Health News:Biggest Ever Weekly Rise in Ebola Cases, U.N. Agency Says 2Health News:Biggest Ever Weekly Rise in Ebola Cases, U.N. Agency Says 3Health News:ReputationChief.Com Announces a New Service ‘Remove Bad Reviews’ 2Health News:Dental Implants Dentist, Kevin Sands DDS, Is Now Offering Mini Implants 2
(Date:8/29/2014)... Ebola researcher from the University of Texas Medical Branch at ... three monoclonal antibodies can completely protect monkeys against a lethal ... at a time when the disease is severe. , Thomas ... for Nature discussing advances in Ebola treatment research. ... among the most deadly of pathogens, with fatality rates of ...
(Date:8/29/2014)... the repeated climatic shifts over the last 120,000 ... diversity, a team of researchers led by City ... developed a new biodiversity metric called "phylogeographic endemism." ... genetic variation within species is restricted in geographical ... biology, and 14 other researchers from institutions in ...
(Date:8/29/2014)... type and number of connections in transcription factor networks ... in a study published in PLOS Computational Biology ... assortativity signature contributes to a network,s resilience against mutations. ... out-out assortativity of TFN models has a greater effect ... types of assortativity," said Dov A. Pechenick, PhD, lead ...
Breaking Biology News(10 mins):Leading Ebola researcher at UTMB says there's an effective treatment for Ebola 2CCNY team defines new biodiversity metric 2Assortativity signatures of transcription factor networks contribute to robustness 2
Other Contents